Last reviewed · How we verify
Aponeuron — Competitive Intelligence Brief
phase 2
amfetaminil
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Aponeuron (AMFETAMINIL). Aponeuron works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, to enhance alertness and wakefulness.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aponeuron TARGET | AMFETAMINIL | phase 2 | amfetaminil |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (amfetaminil class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aponeuron CI watch — RSS
- Aponeuron CI watch — Atom
- Aponeuron CI watch — JSON
- Aponeuron alone — RSS
- Whole amfetaminil class — RSS
Cite this brief
Drug Landscape (2026). Aponeuron — Competitive Intelligence Brief. https://druglandscape.com/ci/amfetaminil. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing